1-855-378-42281-855-378-4228
One of the outpatient treatment options for individuals in Hollywood who are battling with opioid abuse and addiction is opioid maintenance therapy. Licensed facilities and doctors are authorized to dispense certain medications to opioid addicted individuals, many of which are opioid-based themselves and are addiction. With low enough doses the client does not experience being high and also doesn't experience acute cravings and isn't experiencing opioid withdrawal. Methadone is the first medication tried for this purpose, but there are alternative options currently to select from.
Methadone is an opiate and is meant to be taken at an out-patient clinic certified to administer the med, that is taken daily as a pill or liquid. The price of the med is around $150 a month. Buprenorphine is also an opiate based med, and is in pill form often taken one day on, one day off. But different from Methadone that can only be administered in highly well-regulated clinics, Buprenorphine can be prescribed and dispensed in doctor's offices. The price monthly of buprenorphine is around three hundred dollars /month for the generic of the medication. There is also a type of buprenorphine that contains naloxone, that is a drug which blocks the effects of opioids. Someone taking this formulation, also known as Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It too is taken on a daily basis, and is priced approximately $450 monthly. Naltrexone is another med taken in opioid maintenance therapy, but unlike the other drugs mentioned it's an opiate blocker and is not an opioid. A person has the choice to take this medication as a monthly injection, and that is called Vivitrol. As an opioid blocker, the drug prevents a person from experience high feelings from opioids, and therefore lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 a month.
For All Drug and Alcohol Treatment Programs In Hollywood, Click Here.
